BEDFORD, Ohio, Feb.

WHITE PLAINS, N.Y., Feb.

DALLAS, December 19, 2011 /PRNewswire/ -- The "Acute Myeloid Leukemia Therapeutics Market in G8 Countries (2010 - 2020)" analyzes and studies the major market drivers,

Adding a drug that activates genes to frontline combination therapy for acute myeloid leukemia resulted in an 85 percent remission rate after initial treatment, researchers at The University of Texas MD Anderson Cancer Center reported at the 53rd Annual Meeting of the American Society of Hematology.

A new discovery in mice by researchers at Wake Forest Baptist Medical Center may one day allow doctors to spare some patients with acute myeloid leukemia (AML) from toxic treatments, while also opening the door for new therapeutic research.